🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma

Recruitingn/aAges 21 Years - 105 YearsAllMedical University of Vienna
NCT03423758 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

There is increasing evidence that there are genetic risk factors for several forms of glaucoma, such as glaucoma caused by pseudoexfoliation syndrome (PXF) ,primary angle closure glaucoma (PACG) and primary open-angle glaucoma (POAG). The aim of the present prospective, multi-center, case-control study is to identify susceptibility genes/loci for PXF, PACG and POAG using a whole genome association (WGA) approach.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. For patients with PXF: * Patients with confirmed pseudoexfoliation syndrome (exfoliation glaucoma / pseudoexfoliation of the lens) in the medical history * Informed consent * Age 50 years or more 2. For patients with PACG: * Patients with confirmed acute primary angle closure (PAC) or primary angle closure glaucoma (PACG) in the medical history * Informed consent * Age 21 years or more 3. For healthy controls: * No evidence of PXF, glaucoma or uveitis during clinical examination or in the medical history * No evidence of major ocular disease such as diabetic retinopathy, age related macular degeneration or conditions with genetic background during clinical examination or in the medical history * Age more than 60 years * Informed consent 4. For patients with POAG: * Patients with confirmed primary open angle glaucoma (POAG) * No evidence of exfoliation glaucoma / pseudoexfoliation of the lens or pigment glaucoma * Informed consent * Age 30 or more Exclusion Criteria: * Patients and subjects will be excluded if one or more of the following criteria apply: * Neovascular glaucoma * Active or history of uveitis * Secondary angle closure such as neovascular glaucoma or uveitis/inflammatory eye disease * Inability to give informed consent
💊

What it tests

  • Blood sample
📍

Where

1 site
Department of Clinical Pharmacology, Medical University of Vienna
Vienna, Austria
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy